Generic pharmaceutical company BDR Pharmaceuticals announced the launch of Cabozantinib which can treat metastatic medullary thyroid cancer, advanced renal cell carcinoma and hepatocellular carcinoma.

Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma. The drug works by blocking (inhibiting) the signals inside cancer cells that make them grow and divide. In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).

Raheel Shah, Director of Business Development, BDR Pharmaceuticals, said: "World-class treatment at a reasonable rate was the main reason for launching the drug in India. Though we have been outstretched in all departments to deliver on COVID treatment on an emergency basis, we have not allowed this to hamper our efforts on other equally important priority segments, including oncology. The result is the advent of the development of this new generic cancer molecule called Cabozantinib(Cabozanib). "

The medicine will be available in the next couple of days as it has been approved by the DGCI.